YOLFTbeta
Palvella Therapeutics, Inc

Palvella Therapeutics, Inc

PVLA · NASDAQ · Healthcare / Biotechnology

152.48USD-0.70 (-0.46%)

Price History

Full chart

Market Stats

Previous Close153.18
Open153.00
Day Range149.81 – 156.71
52-Week Range60.49 – 161.38
Volume240.30K
Market Cap2.01B
P/E (TTM)0.00
Forward P/E0.00
EPS-4.90
Dividend Yield0.00%
50-Day Avg148.94
200-Day Avg122.95

About

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Wesley H. Kaupinen
  • Employees29
  • Headquarters353 W. Lancaster Avenue, Wayne, PA, United States, 19087, USA
  • Websitehttps://palvellatx.com

Leadership

  • Mr. Wesley H. KaupinenFounder, President, CEO & Director
  • Mr. Matthew E. KorenbergCFO, Corporate Secretary & Treasurer · b. 1975
  • Ms. Kathleen GoinChief Operating Officer · b. 1971
  • Dr. Jeffrey Martini Ph.D.Chief Scientific Officer · b. 1978

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue12.43M5.37M2.93M5.83M25.27M29.10M46.28M29.32M31.42M25.90M000
Growth (%)--56.83%-45.35%+98.87%+333.46%+15.14%+59.03%-36.64%+7.14%-17.56%-100.00%--
Cost of Revenue--------2.37M2.78M---
Gross Profit-------29.32M29.05M23.12M---
Gross Margin-------100.00%92.46%89.27%---
Operating Expense-------63.24M80.88M66.60M---
Operating Income553.83K-7.20M-13.08M-22.76M-14.59M-30.83M-27.16M-33.92M-51.83M-43.47M-11.87M-14.10M-38.60M
Operating Margin4.46%-134.17%-446.15%-390.31%-57.74%-105.94%-58.68%-115.68%-164.97%-167.84%---
EBITDA944.81K-6.83M-13.55M-22.28M-16.18M-26.50M-24.43M-34.94M-43.37M-30.50M18.69M-13.12M-35.90M
EBITDA Margin7.60%-127.27%-462.04%-382.03%-64.00%-91.05%-52.79%-119.15%-138.04%-117.74%---
Net Income66.20K-9.85M-14.06M-22.80M-17.65M-26.75M-25.47M-37.23M-45.74M-33.28M18.69M-17.43M-41.72M
Net Income Margin0.53%-183.60%-479.50%-391.00%-69.82%-91.93%-55.03%-126.97%-145.58%-128.47%---
R&D9.41M5.60M7.64M19.70M21.92M40.92M54.36M44.22M64.20M50.21M8.79M8.15M22.84M
R&D as % of Total Revenue75.74%104.38%260.74%337.83%86.71%140.61%117.47%150.80%204.33%193.85%---
Interest Expense493.94K2.65M--------04.32M5.82M
Interest Expense % of Total Revenue3.97%49.49%-----------

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-------105.01M153.56M16.52M7.55M88.23M59.56M
Total Liabilities-------73.98M102.81M39.70M11.43M25.63M31.58M
Total Equity-------31.03M50.76M-23.17M-3.88M62.61M27.98M
Cash-------70.44M117.76M16.05M7.35M83.60M57.98M
Total Debt-------16.96M14.89M13.10M78.66M11.94M633.00K
Net Debt--------53.47M-102.87M-16.05M-7.35M-83.60M-57.35M

Cash Flow

Currency: USD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-45.90M-7.66M-14.84M-13.70M-10.84M-25.01M
Investing Cash Flow39.21M-949.00K-21.24M---
Financing Cash Flow10.12M59.13M9.57M5.00M87.09M-660.00K
Capital Expenditure2.73M949.00K1.04M000
Free Cash Flow-48.62M-8.61M-14.84M-13.70M-10.84M-25.01M
FCF to OCF105.94%112.39%100.00%100.00%100.00%100.00%

Earnings

Report DateDec 31, 2014Jun 3, 2015Aug 13, 2015Nov 12, 2015Mar 23, 2016May 12, 2016Aug 10, 2016Nov 10, 2016Mar 23, 2017May 11, 2017Aug 10, 2017Nov 9, 2017Mar 9, 2018May 10, 2018Aug 9, 2018Nov 7, 2018Mar 20, 2019May 8, 2019Aug 7, 2019Nov 11, 2019Mar 12, 2020May 11, 2020Aug 10, 2020Nov 4, 2020Mar 30, 2021May 17, 2021Aug 4, 2021Nov 2, 2021Mar 1, 2022May 11, 2022Aug 4, 2022Nov 2, 2022Mar 29, 2023May 10, 2023Aug 3, 2023Nov 8, 2023Mar 27, 2024May 8, 2024Aug 1, 2024Oct 30, 2024Dec 31, 2024May 15, 2025Aug 14, 2025Nov 10, 2025Dec 31, 2025May 7, 2026Aug 4, 2026Nov 10, 2026
EPS Estimate-------------0.07-0.02-0.01-0.12-0.18-0.20-0.22-0.17-0.28-0.17-0.17-0.13-0.23-0.17-0.22-0.24-0.14-0.12-0.11-0.16-0.23-0.18-0.16-0.11-0.12-0.06-0.03--0.60-3.40-0.77-0.85-0.91-0.93-1.16-1.63
EPS Actual-11.38-7.32-9.60-8.07-5.83-8.36-11.52-11.51-12.19-14.85-18.59-12.7214.40-0.17-0.30-8.80-17.60-16.00-19.20-4.00-4.80-5.60-7.20-20.80-20.80-5.60-20.00-19.20-12.00-5.60-11.20-10.40-8.80-14.404.00-8.70-3.71-3.95-2.76-2.19-5.37-0.74-0.86-1.03-1.08-1.20-1.52-
Surprise------------20671.43%-750.00%-2908.00%-7233.33%-9677.78%-7900.00%-8627.27%-2252.94%-1614.29%-3194.12%-4135.29%-15900.00%-8846.24%-3194.12%-8990.91%-7791.49%-8788.89%-4769.57%-10081.82%-6400.00%-3726.09%-7747.41%2652.65%-7810.45%-2988.92%-6491.17%-9112.33%--798.74%78.24%-11.69%-21.18%-18.58%-29.03%-31.03%-
Timing-----------------------------------------Pre-marketPre-marketAfter-hours-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap2.01B
Enterprise Value1.90B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book9.93
EPS-4.90
Book Value15.07
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-46.63%
Return on Assets-22.06%
Shares Outstanding14.41M
Shares Float10.68M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 9 analystsTarget 230.53
  • Strong Buy
    7
  • Buy
    2

Ownership Breakdown

Institutions
104.76%
Insiders
11.59%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    1.15M8.01%
  • Bvf Inc
    960.99K6.67%
  • Jennison Associates LLC
    960.62K6.67%
  • Frazier Life Sciences Management, L.P.
    882.40K6.12%
  • First Light Asset Management, LLC
    771.90K5.36%
  • BlackRock Inc
    686.85K4.77%
  • Frontier Capital Management CO Inc
    478.83K3.32%
  • Vanguard Capital Management, LLC
    477.29K3.31%
  • State Street Corp
    459.00K3.19%
  • Federated Hermes Inc
    433.01K3.01%
  • T. Rowe Price Associates, Inc.
    402.56K2.79%
  • Woodline Partners LP
    317.52K2.20%
  • AllianceBernstein L.P.
    262.83K1.82%
  • Siren, L.L.C.
    257.49K1.79%
  • PRIMECAP Management Company
    256.18K1.78%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    431.37K2.99%
  • Vanguard MStar Total Stk Mkt Idx Invest
    389.11K2.70%
  • iShares Russell 2000 ETF
    279.12K1.94%
  • Federated Hermes Kaufmann R
    276.56K1.92%
  • PGIM Jennison Small Company A
    237.76K1.65%

Stock Splits

  • Apr 23, 20241:80